Jayson MacLean

About Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

ATS Automation could be ready for a rally, this investor says

January 15, 2019 by Jayson MacLean

Factory automation company ATS Automation (ATS Automation Stock Quote, Chart TSX:ATA) took it on the chin last quarter but the stock could be in for a … [Read more...] about ATS Automation could be ready for a rally, this investor says

Echelon Wealth Partners reveals its Top Stock Picks for 2019

January 14, 2019 by Jayson MacLean

Profound Medical Corp. (Profound Medical Stock Quote, Chart TSX:PRN), kneat.com (kneat.com Stock Quote, Chart TSXV:KSI) and Photon Control (Photon … [Read more...] about Echelon Wealth Partners reveals its Top Stock Picks for 2019

There’s still tons of upside in Acerus Pharmaceuticals, Mackie Research says

January 14, 2019 by Jayson MacLean

Specialty pharma company Acerus Pharmaceuticals (Acerus Pharmaceuticals Stock Quote, Chart TSX:ASP) has reported an anticipated shortage in its … [Read more...] about There’s still tons of upside in Acerus Pharmaceuticals, Mackie Research says

The Celestica selloff is overdone, this investor says

January 14, 2019 by Jayson MacLean

Shareholders of outsourced electronics manufacturer Celestica (Celestica Stock Quote, Chart TSX, NYSE:CLS) may be worried about the stock’s plunge … [Read more...] about The Celestica selloff is overdone, this investor says

New deal for Knight Therapeutics doesn’t move the needle, says Mackie Research

January 11, 2019 by Jayson MacLean

Commercial-stage specialty pharma company Knight Therapeutics (Knight Therapeutics Stock Quote, Chart TSX:GUD) has entered into a licensing agreement … [Read more...] about New deal for Knight Therapeutics doesn’t move the needle, says Mackie Research

AcuityAds has a 95 per cent upside, says Echelon Wealth

January 11, 2019 by Jayson MacLean

Digital advertising company AcuityAds Holdings (AcuityAds Stock Quote, Chart TSXV:AT) is in the right place at the right time, says analyst Rob Goff … [Read more...] about AcuityAds has a 95 per cent upside, says Echelon Wealth

Christine Poole explains why she doesn’t own BlackBerry stock

January 11, 2019 by Jayson MacLean

BlackBerry (BlackBerry Stock Quote, Chart TSX, NYSE:BB) may have successfully pivoted away from smartphones and into software, but Christine Poole of … [Read more...] about Christine Poole explains why she doesn’t own BlackBerry stock

These cannabis stocks will rock in 2019, GMP Securities says

January 10, 2019 by Jayson MacLean

2018 was a rocky year for most market sectors but for healthcare and, in particular, for cannabis stocks the peaks and valleys were extreme. Canadian … [Read more...] about These cannabis stocks will rock in 2019, GMP Securities says

TSO3 Inc has a 181 per cent upside, says Echelon Wealth

January 10, 2019 by Jayson MacLean

Look for medical tech company TSO3 (TSO3 Stock Quote, Chart TSX:TOS) to become EBITDA-positive this year, says Echelon Wealth Partners analyst Douglas … [Read more...] about TSO3 Inc has a 181 per cent upside, says Echelon Wealth

CGI Group is the Rodney Dangerfield of tech stocks, this portfolio manager says

January 10, 2019 by Jayson MacLean

It’s tough being a Canadian tech company sometimes. Not only are you competing for attention with the much bigger Amazons and Microsofts of the … [Read more...] about CGI Group is the Rodney Dangerfield of tech stocks, this portfolio manager says